Bristol Myers Squibb Company v. Lupin Inc

Court

District Court, D. New Jersey (D.N.J.)
Official Court Website →

Assigned judge

Michael A. Shipp · 5,509 cases in index

Docket number

3:20-cv-07810

Cause

15:1126 Patent Infringement
15 U.S.C. § 1126

Nature of suit

835 Patent - Abbreviated New Drug Application(ANDA)
Hatch-Waxman patent disputes over a generic-drug (ANDA) application.

Jurisdiction

Federal Question

Jury demand

None

Date filed

06/25/2020

Date terminated

07/20/2021

623 Patent - ANDA cases in this court are indexed here.

Parties

• plaintiff · Bristol-Myers Squibb Pharmaceuticals & Biotechnology · 9426 cases
• defendant · Lupin Inc · 10 cases

Part of a Larger Litigation Pattern

This is one of 11 Patent - ANDA cases in our index naming Lupin Inc — a possible mass-tort or coordinated-litigation cluster.

• Indivior Inc v. Lupin Inc
  District Court, D. DelawareFiled 06/20/2025
• Theravance Biopharma R&D Ip, LLC v. Lupin Inc
  District Court, D. DelawareFiled 02/17/2023
• Galderma Laboratories L.P v. Lupin Inc
  District Court, D. DelawareFiled 12/03/2021
• Novartis Pharmaceuticals Corporation v. Lupin Inc
  District Court, D. DelawareFiled 07/29/2021
• Jazz Pharmaceuticals Ireland Limited v. Lupin Inc
  District Court, D. New JerseyFiled 07/28/2021
• Ferring Pharmaceuticals Inc v. Lupin Inc
  District Court, D. DelawareFiled 05/16/2019

About Patent - ANDA Lawsuits

ANDA patent cases arise when a generic-drug maker files an Abbreviated New Drug Application and the brand-name patent holder sues for infringement under the Hatch-Waxman Act.

Frequently Asked Questions

What is Bristol Myers Squibb Company v. Lupin Inc?

Bristol Myers Squibb Company v. Lupin Inc is a federal patent - anda lawsuit filed on 06/25/2020 in the District Court, D. New Jersey. The case was terminated on 07/20/2021. ANDA patent cases arise when a generic-drug maker files an Abbreviated New Drug Application and the brand-name patent holder sues for infringement under the Hatch-Waxman Act.

What type of case is this?

It is classified as “Patent - ANDA” under the federal nature-of-suit system. ANDA patent cases arise when a generic-drug maker files an Abbreviated New Drug Application and the brand-name patent holder sues for infringement under the Hatch-Waxman Act.

What court is the case in?

The case is in the District Court, D. New Jersey, docket number 3:20-cv-07810.

When was the case filed?

Bristol Myers Squibb Company v. Lupin Inc was filed on 06/25/2020. It was terminated on 07/20/2021.

What law is the case brought under?

The docket lists the cause as 15 U.S.C. § 1126.